PDF(Pubmed)
Abstract：
UNASSIGNED: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity.
UNASSIGNED: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.
UNASSIGNED: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.
UNASSIGNED: Abrocitinib is a promising agent for the treatment of MMP with oral involvement.
UNASSIGNED: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.
UNASSIGNED: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.
UNASSIGNED: Abrocitinib is a promising agent for the treatment of MMP with oral involvement.
摘要：
■粘膜类天疱疮（MMP），一种罕见的自身免疫性泡状和糜烂性疾病，可能会影响多个粘膜，口腔是最常见的受影响的部位。其治疗取决于粘膜受累的部位和疾病的严重程度。
■一名62岁女性MMP患者，主要累及口腔，强烈拒绝全身性皮质类固醇或免疫抑制剂，并成功使用abrocitinib治疗，一种具有良好安全性的高选择性JAK-1抑制剂。
■该病例证明了abrocitinib治疗以口服为主的MMP的良好疗效和安全性。
■阿布西替尼是一种有前途的药物，用于口服参与治疗MMP。
■一名62岁女性MMP患者，主要累及口腔，强烈拒绝全身性皮质类固醇或免疫抑制剂，并成功使用abrocitinib治疗，一种具有良好安全性的高选择性JAK-1抑制剂。
■该病例证明了abrocitinib治疗以口服为主的MMP的良好疗效和安全性。
■阿布西替尼是一种有前途的药物，用于口服参与治疗MMP。
